Halozyme Therapeutics HALO Debt securities - current
Debt securities - current at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's debt securities - current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Halozyme Therapeutics's debt securities - current?
- Halozyme Therapeutics (HALO) reported debt securities - current of $8.87M in Q1 2026.
- How has Halozyme Therapeutics's debt securities - current changed year-over-year?
- Halozyme Therapeutics's debt securities - current decreased by 98.4% year-over-year, from $571.59M to $8.87M.
- What is the long-term trend for Halozyme Therapeutics's debt securities - current?
- Over 3 years (2022 to 2025), Halozyme Therapeutics's debt securities - current has grown at a -58.8% compound annual growth rate (CAGR), from $128.6M to $9M.